Efficacy and safety of bisoprolol 5 mg plus amlodipine 5 mg in patients with hypertension uncontrolled on monotherapy with 5 mg of amlodipine, a phase III multicenter, randomized, double-blind, placebo-controlled clinical trial – the AMCOR study

References

• Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the management of arterial hypertension. J Hypertens. 2018;36(12):2284–2309. doi: 10.1097/HJH.0000000000001961.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, American Society of Hypertension Writing Group, et al. Combination therapy in hypertension. J Clin Hypertens. 2011;13(3):146–154. doi: 10.1111/j.1751-7176.2010.00397.x.
   PubMed Web of Science ®Google Scholar
• An J, Derington CG, Luong T, et al. Fixed-dose combination medications for treating hypertension: a review of effectiveness, safety, and challenges. Curr Hypertens Rep. 2020;22(11):95. doi: 10.1007/s11906-020-01109-2.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the european society of cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484.
   PubMed Web of Science ®Google Scholar
• Aoun M, Tabbah R. Beta-blockers use from the general to the hemodialysis population. Nephrol Ther. 2019;15(2):71–76. doi: 10.1016/j.nephro.2018.10.003.
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. The place of beta-blockers in cardiovascular medicine. Cardiologia. 1995;40(11):829–843.
   PubMedGoogle Scholar
• Jeffers BW, Robbins J, Bhambri R, et al. A systematic review on the efficacy of amlodipine in the treatment of patients with hypertension with concomitant diabetes mellitus and/or renal dysfunction, when compared with other classes of antihypertensive medication. Am J Ther. 2015;22(5):322–341. doi: 10.1097/MJT.0000000000000202.
   PubMed Web of Science ®Google Scholar
• Murdoch D, Heel RC. Amlodipine. Drugs. 1991;41(3):478–505. doi: 10.2165/00003495-199141030-00009.
   PubMed Web of Science ®Google Scholar
• Smith C, Teitler M. Beta-blocker selectivity at cloned human beta1-and beta2-adrenergic receptors. Cardiovasc Drugs Ther. 1999;13(2):123–126. doi: 10.1023/A:1007784109255.
   PubMed Web of Science ®Google Scholar
• Nuttall S, Routledge H, Kendall M. A comparison of the β1‐selectivity of three β1‐selective β‐blockers. J Clin Pharm Ther. 2003;28(3):179–186. doi: 10.1046/j.1365-2710.2003.00477.x.
   PubMedGoogle Scholar
• Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(2):90–98. doi: 10.1016/j.jash.2010.03.001.
   PubMed Web of Science ®Google Scholar
• Gottwald-Hostalek U, Sun N, Barho C, et al. Management of hypertension with a fixed-dose (single-pill) combination of bisoprolol and amlodipine. Clin Pharmacol Drug Dev. 2017;6(1):9–18. doi: 10.1002/cpdd.309.
   PubMed Web of Science ®Google Scholar
• Hostalek U, Czarnecka D, Koch EM. Treatment of hypertensive patients with a fixed-dose combination of bisoprolol and amlodipine: results of a cohort study with more than 10,000 patients. Cardiol Ther. 2015;4(2):179–190. doi: 10.1007/s40119-015-0045-z.
   PubMedGoogle Scholar
• Chen JM, Heran BS, Perez MI, et al. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev. 2010;1: CD007185. doi: 10.1002/14651858.CD007185.pub2.
   Google Scholar
• Liu J, Li X, Zhang H, et al. S-amlodipine-bisoprolol combination therapy caused elevated transaminases and triglyceride levels in healthy chinese subjects: a randomized controlled, open-label, multiple-dose pharmacokinetic interaction study. Expert Opin Drug Metab Toxicol. 2019;15(9):687–695. doi: 10.1080/17425255.2019.1650913.
   PubMed Web of Science ®Google Scholar
• Shirure P, Tadvi N, Bajait C, et al. Comparative effect of fixed dose combination of amlodipine + bisoprolol versus amlodipine and bisoprolol alone on blood pressure in stage-2 essential hypertensive patients. Int J Med Res Health Sci. 2012;1(1):13–19.
   Google Scholar
• Hostalek-Gottwald U, Gaciong Z. A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension. Curr Med Res Opin. 2022;38(7):1047–1053. doi: 10.1080/03007995.2022.2072087.
   PubMed Web of Science ®Google Scholar
• Gaciong Z. Clinical efficacy of a combination of bisoprolol and amlodipine. In: Gaciong Z, Gottwald-Hostalek U, editors. 10 Years of experience with a fixed-dose combination of bisoprolol and amlodipine. London: Springer Healthcare Education; 2022. p. 71–94.
   Google Scholar
• European Medicines Agency. 2016. Guideline on clinical investigation of medicinal products in the treatment of hypertension. Available from: https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-hypertension.
   Google Scholar
• Gottwald-Hostalek U, Li L, Montenegro P. Bisoprolol/amlodipine combination therapy improves blood pressure control in patients with essential hypertension following monotherapy failure. Curr Med Res Opin. 2016;32(10):1735–1743. doi: 10.1080/03007995.2016.1205573.
   PubMed Web of Science ®Google Scholar
• Preston RA, Materson BJ, Reda DJ, et al. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a department of veterans affairs cooperative study. Arch Intern Med. 2000;160(10):1449–1454. doi: 10.1001/archinte.160.10.1449.
   PubMedGoogle Scholar
• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898. doi: 10.1056/NEJMoa0801369.
   PubMed Web of Science ®Google Scholar
• Patel HC, Hayward C, Ozdemir BA, et al. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. Hypertension. 2015;65(2):401–406. doi: 10.1161/HYPERTENSIONAHA.114.04640.
   PubMed Web of Science ®Google Scholar
• Lewin A, Punzi H, Xiaohui L, et al. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized-placebo-controlled trial. Clin Ther. 2013;35(2):142–152. doi: 10.1016/j.clinthera.2012.12.015.
   PubMed Web of Science ®Google Scholar
• Pool J, Schmieder R, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20(1):11–20. doi: 10.1016/j.amjhyper.2006.06.003.
   PubMed Web of Science ®Google Scholar
• Mehta S, Shah M, Shah A. Efficacy and tolerability of a fixed dose combination of amlodipine and bisoprolol in essential hypertension. Indian Pract. 2005;58(12):751–759.
   Google Scholar
• Rana R, Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. Indian Pract. 2008;61(4):225–234.
   Google Scholar
• Chesnikova A, Safronenko V, Kolomatskaia O. Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease. Kardiologiia. 2014;54(9):17–23. doi: 10.18565/cardio.2014.9.17-23.
   PubMed Web of Science ®Google Scholar
• Fujii R, Restrepo M, Pepe C, et al. Efficacy and safety of amlodipine and bisoprolol in hypertension treatment: a systematic review. Value in Health. 2015;18(3):A132. doi: 10.1016/j.jval.2015.03.769.
   Web of Science ®Google Scholar